Clinical Trial Update: Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating topical Sm29 with meglumine antimoniate for Cutaneous Leishmaniasis (American form) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• Meglumine antimoniate (meglumine antimoniate)
• Sm29 topical (Sm29 topical formulation)

Snippet

Sponsor: Hospital Universitário Professor Edgard Santos | Conditions: Cutaneous Leishmaniasis, American | Phase 1, Phase 2 | Status: COMPLETED